Results 151 to 160 of about 1,093,896 (249)

Regulating Lipid Metabolism in Cancer: The Therapeutic Potential of Traditional Chinese Medicine

Phytotherapy Research, EarlyView.
By regulating the reprogramming of lipid metabolism in tumor cells, TCM provides a novel strategy for antitumor therapy with reduced toxicity and enhanced efficacy. ABSTRACT Lipid metabolic reprogramming is a key feature of tumor cells to adapt to the microenvironment and plays an important role in tumor growth, invasion, and metastasis.
Yufeng Gao, Huiming Huang, Xuejiao Wei, Xiaoxue Wang, Wanying Xie, Xinyu Qiu, Fei Wang, Zhuguo Wang, Ruoxin Zhang, Yilin Cai, Changhai Qu, Zhongdong Hu   +11 more
wiley   +1 more source

Evaluating the safety of Janus kinase inhibitors in the management of severe immune-related adverse events. [PDF]

J Immunother Cancer
Lee E, Karagenova R, Fuksman L, Katyal P, Lim T, Sun V, Reynolds KL, Semenov YR.   +7 more
europepmc   +1 more source

Pregnancy in CTD‐interstitial lung disease: Current evidence, clinical challenges, and a proposed management algorithm

Rheumatology &Autoimmunity, EarlyView.
Summary of pregnancy management in CTD‐ILD across preconception, antenatal, and postpartum phases, emphasizing risk stratification and multidisciplinary care. 6MWT, 6‐min walk test; CTD‐ILD: connective tissue disease‐interstitial lung disease; DLCO, diffusion capacity of the lung for carbon monoxide; FVC, forced vital capacity; MDT, multidisciplinary ...
Khaled Aldhuaina, Ghaydaa Aldabie, Mohammad Abdulsalam, Ali Jawad   +3 more
wiley   +1 more source

Janus Kinase Inhibitors and Body Weight: Current Evidence and Potential. [PDF]

Life (Basel)
Kraev K, Basheva-Kraeva Y, Uchikova M, Uchikov P, Hristov B, Valova S, Doykov M, Stanchev D, Boyukliev A, Batalov Z.   +9 more
europepmc   +1 more source

Intersection of systemic lupus erythematosus and autoimmune thyroid disease: Shared pathophysiology, epidemiology, diagnosis, and management

Rheumatology &Autoimmunity, EarlyView.
A proposed mechanistic framework of systemic lupus erythematosus (SLE) and autoimmune thyroid disease (AITD) pathogenesis. In Stage 1, genetically susceptible individuals harbor risk variants within major histocompatibility complex (HLA) and non‐HLA loci that impair central and peripheral immune tolerance mechanisms within the thymic and peripheral ...
Elisa Elisa, Awalia Awalia, Deasy Ardiany, Henry Sutanto   +3 more
wiley   +1 more source

A meta-analysis of the efficacy and safety of Janus kinase inhibitors in patients with ulcerative colitis. [PDF]

Medicine (Baltimore)
Yang Q, Yan Y.
europepmc   +1 more source

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley   +1 more source

Real-World Experience with Janus Kinase Inhibitors in Severe Refractory Hidradenitis Suppurativa: A Retrospective Case Series. [PDF]

Clin Cosmet Investig Dermatol
Dai Y, Han Y, Zhang S, Chen H, Yi Q, Jiang X.   +5 more
europepmc   +1 more source

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

Allergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud, Lene Heise Garvey, Elizabeth Phillips, Michael Ardern‐Jones, Sevim Bavbek, Patrizia Bonadonna, Jean‐Christoph Caubet, Ana‐Maria Copaescu, Valentina Gueli, Jose Julio Laguna, Ricardo Madrigal‐Burgaleta, Francesca Mori, Vito Sabato, Maria J Torres, Knut Brockow   +14 more
wiley   +1 more source

Efficacy of abrocitinib in patients with atopic dermatitis resistant to Janus kinase inhibitors. [PDF]

Skin Health Dis
Ippoliti E, Gori N, Coscarella G, Antonelli F, Cannizzaro MV, Peris K.   +5 more
europepmc   +1 more source